🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Plymouth
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Plymouth

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC12 Hoffmann-La Roche9 Eli Lilly and Company9 AbbVie8 GlaxoSmithKline7
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
127 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856Urothelial Cancer
Astellas Pharma Global Development, Inc.
Phase 3
886
Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton
2020-03-30
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
Hoffmann-La Roche
Phase 2/3
325
London, Northwood, Oxford, Plymouth
2020-01-29
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NCT04006210Parkinson's Disease
NeuroDerm Ltd.
Phase 3
381
London, Newcastle, Plymouth
2019-09-30
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005Multiple Sclerosis, Primary Progressive
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Active, closed
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
NCT03104517Stress Urinary Incontinence
Cook MyoSite
Phase 3
96
Plymouth
2019-04-23
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
EMD Serono Research & Development Institute, Inc.
Phase 3
205
London, Northwood, Plymouth
2019-03-22
Active, closed
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03671018B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2
422
Cambridge, Plymouth
2018-09-25
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
Genmab
Phase 1/2
666
Manchester, Plymouth, Southampton, Sutton
2018-06-26
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London
2017-12-18
Active, closed
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506Primary Biliary Cirrhosis
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe
2015-11-27
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Active, closed
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
NCT02365597Urothelial Cancer
Janssen Research & Development, LLC
Phase 2
239
Blackburn, Dundee, Essex, London, Metropolitan Borough of Wirral, Plymouth, Sutton
2015-04-22
Active, closed
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926Mantle Cell Lymphoma (MCL)
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
NCT02180724Waldenström Macroglobulinemia (WM)
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Rows per page Showing 101–125 of 127
Previous 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/plymouth

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.